Cybersight AI is a clinical decision support tool for ophthalmology
It can detect diabetic retinopathy, glaucoma and other conditions from fundus images
Available exclusively in low- and middle-income countries, at no cost to end-users
Why use Cybersight AI?
Speed/efficiency: reduce the time to screen and make a referral decision from days or weeks to minutes.
Task shifting: non-medical staff can be easily trained to use Cybersight AI for screening.
Increased referral compliance: a clinical trial showed patients who received immediate referral advice from Cybersight AI were 30% more likely to follow through with their referral.
Machine Mentoring: learn through on-screen annotation and quantification of biomarkers and other pathologies.
There are 2 versions of Cybersight AI:
Occasional Use
Anyone with Cybersight Consult
Mobile app
Results in 1 minute
Standard PDF report with AI results
High Volume Screening
DR screening programs
Results in 5 seconds
Customized reports & protocols
Regulatory alignment
Cybersight AI Evidence & Impact
Feasibility and Acceptance of Artificial Intelligence-Based Diabetic Retinopathy Screening in Rwanda
Impact of Artificial Intelligence Assessment of Diabetic Retinopathy on Referral Service Uptake in a Low-Resource Setting: The RAIDERS Randomized Trial
Artificial Intelligence, Cybersight Detection of Diabetic Retinopathy in the Elderly in Vietnam
Đánh Giá Tình Trạng Võng Mạc Trên Bệnh Nhân Đái Tháo Đường Tại Bệnh Viện Đa Khoa Đức Giang
Frequently Asked Questions
No, Cybersight AI is camera-agnostic. Any high-quality fundus camera can be used.
A Randomized Control Trial in Rwanda showed the sensitivity of Cybersight AI for referable DR was 92% (95% CI 0.863%, 0.968%), with a specificity of 85% (95% CI 0.751%, 0.882%).
Cybersight AI was developed and is maintained in-house by Orbis International.
No, Cybersight AI is not FDA approved or CE marked.
No, Cybersight AI requires an internet connection. If you have a strong use case for using Cybersight AI offline in a low- or middle-income country, please contact us to discuss further.
Yes, the high-volume screening version of Cybersight AI has two models: one for desktop cameras, and another for handheld cameras.
No, we do not license Cybersight AI for use in high-income countries. Our mission is exquisitely focused on meeting the needs of LMICs.
Access to Cybersight AI is restricted to authorized users with a username and password. Users of Cybersight AI only have access to data in workspaces they have been granted access to (i.e. their own patients).
A limited amount of data is collected about patients. By default, all Cybersight AI records are anonymous. Implementers may optionally choose to collect a patient identifier.
Cybersight AI is hosted in secure cloud hosting facilities. Data are encrypted both in transit and in storage, and we employ industry-standard security features such as firewalls and security monitoring software.
For more information, see the Cybersight Terms & Conditions and the Orbis Privacy Policy.
Have a question? Feel free to contact us, we’ll be glad to hear from you.